contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


bioretec-ltds-financial-statements-and-annual-report-2025-published

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Bioretec operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio includes, for example, implants for pediatric and adult orthopedics and other materials for bone and soft tissue injuries. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic region.

Thank you @Vino_Pino ! I completely missed this. I’ve even been checking LinkedIn from time to time to see what Paavola’s situation is after the sudden departure from NGH. And today was so strange; while I was writing my previous message, I had already double-checked several times that the CFO on BRETEC’s website was a completely different (female) person. I swear on my honor that the CFO on BRETEC’s website changed to Paavola while I was drafting my previous post. I was really worried about NGH when Paavola left their position with 5 minutes’ notice and the CEO gave downright icy cold “thanks” for absolutely nothing. Now, my feeling regarding this red flag is starting to be quite the opposite. (Perhaps) more on this in NGH’s own thread. o tempora - o mores

A couple of months ago                  Inderes              Tuukka Paavola on nimitetty Bioretecin talousjohtajaksi - Inderes    Bioretec Oy Yhtiötiedote 15.1.2026 kello 17:30 EETBiohajoavien ortopedisten implanttien edelläkävijä Bioretec Oy, on nimittänyt Tuukka Paavolan (DI, CFA) talousjohtajaksi 20. tammikuuta 2025...

Does anyone know if there’s a nasty typo at play here or what? Below is the contact information from BRETEC’s 1.5bn share issue announcement by Inderes: Further information Sarah van Hellenberg Hubar-Fisher, CEO, +31 6 1544 8736 Tuukka Paavola, CFO, +358 50 386 0013                   Inderes              Sisäpiiritieto: Bioretec Oy suunnittelee vähintään 5 miljoonan euron ja...    Bioretec Oy Sisäpiiritieto 10.3.2026 klo 21:30Sisäpiiritieto: Bioretec Oy suunnittelee vähintään 5 miljoonan euron ja enintään 15 miljoonan euron, ja enintään 1 500 000 000 uuden osakkeen suuruista...                             Because on BRETEC’s own pages the CFO is … NO WAY! THE CFO CHANGED TO TUUKKA PAAVOLA ON BRETEC’S PAGES WHILE I WAS WRITING THIS MESSAGE!!!                   Bioretec              About us | Bioretec    [vc_row row_height_percent=”0″ override_padding=”yes” h_padding=”2″ top_padding=”3″ bottom_padding=”2″ overlay_alpha=”50″ gutter_size=”3″ column_width_percent=”100″ shift_y=”0″ z_index=”0″ bottom_divider=”gradient” content_parallax=”0″...         Est. reading time: 7 minutes                               So I had to double-check from BRETEC’s own news feed: Further enquiries Sarah van Hellenberg Hubar-Fisher, CEO, +31 6 1544 8736 Tuukka Paavola, CFO, +358 50 386 0013                   Bioretec – 10 Mar 26              Inside information: Bioretec Ltd is planning a rights issue of at least EUR 5...    ViewReleaseInStandardHtml Inside information: Bioretec Ltd is planning a rights issue of at least EUR 5 million and up to EUR […]         Est. reading time: 13 minutes                               Well, how about that. That already three-day-old announcement kept bothering me, and today I decided to check the matter. Has there even been any announcement regarding the appointment of Tuukka Paavola, who left NGH with one day’s notice, to BRETEC?

Share issue stuff. Bioretec’s target in the share issue is that €15 million. If we assume that you own 1,000 shares now and the subscription price per share is €0.10 and the number of new shares is 150 million, then you can subscribe for 4,872 new shares. The amount to be paid is €487.20. If the subscription price is €0.01 and the total number of new shares is 1.5 billion, the amount to be paid is that same €487.20, because the target amount to be raised in the issue is a constant €15 million.

I have exactly the same thoughts. Absolutely incomprehensible bungling that has wiped out 92% of the market value in a year. I also thought a share issue was coming and that I would probably participate. However, those share issue terms were the final red flag (I know, if you subscribe to everything, your ownership stays the same). The fact that they are now seeking authorization for a penny-share issue says everything necessary about the company’s situation; after the issue (if it happens), they’ll do a reverse split anyway. Having fully participated in last summer’s share issue, I can’t help but wonder how the money has been burned through without achieving anything. I tried to rationalize this as a ship that could still turn around, but I just can’t; I should have acknowledged during the strategy change that it no longer meets my investment thesis at all. I’m not falling for the sunk cost fallacy anymore. Following Pyysing’s teachings—“if a position pisses you off, sell immediately”—the entire position accumulated throughout 2022 and from last summer’s share issue has been passed on to new owners.

These rights issues are a mix of psychology and mathematics. Mathematically, one could argue, as already warned in the thread, that if the offering results in 1.5 billion additional shares to raise 15 million, that is 1 cent per share. Often, the stock price also drops to that mathematical level. This happened with Faron, for example: first a 68% drop in 2 days, and then the rest down to the mathematical offering price within a week. It even went below that. There, however, it was “only” 40 million new shares. But now, we are talking about Bioretec. However, the offering does not exist yet, nor do its terms. Analysts can only change their targets once it is known what has been agreed to happen. The shareholders, i.e., the General Meeting, will decide on the possible offering on March 27, 2026. Psychology can support the share price above the mathematics. The most important thing, of course, is to secure funding for as long as possible. And if the company becomes dirt cheap, will someone just snap it up? That reasoning could support the share price. As a disclaimer: I had half of a tracking position in Bioretec. I knew, of course, that there would be offerings, but the potential 1.5 billion new shares spooked me. A low subscription price doesn’t really matter if you subscribe to everything you are entitled to, but a potentially low price forces you to subscribe to everything unless you want to lose a large portion of potential future returns as an owner. Retail investors are being shaken up. I will likely be back on board at some point. I am deep in another rights issue right now… In my opinion, Bioretec has good products and I want to see the Finns succeed. If follow-up surgery to remove the fixation can be avoided in some fracture fixation procedures, it’s a no-brainer. It should be noted, however, that orthopedists like their work, i.e., surgeries. Healthcare organizers/payers/resource managers, on the other hand, would love to eliminate removal surgeries. Both need to be targeted in marketing.

You can think of it as being forced to participate in the share issue now. Otherwise, all your old holdings go down the toilet and you can forget about the whole company. For example, Duell has destroyed its balance sheet with losses, and those who participated in the IPO have lost almost everything. Only crumbs are left if you haven’t participated in the subsequent rescue issues and put new money in later. I participated in the rescue issue myself, and apparently that money will soon be destroyed again, and a new issue may be on the way. Bioretec is on the brink. The issue price is set extremely low to practically force current owners to put new money into the company (a back-against-the-wall choice: provide more money or lose everything you’ve previously put in due to massive share dilution). This motivates many to participate in an issue they otherwise wouldn’t. Alternatively, if current shareholders refuse to participate, that 0.01 euro share price might attract a new outside investor, and the otherwise unsold shares can be peddled to them. This way the issue goes through, the company gets cash in its coffers, and it doesn’t go bankrupt—at least not immediately. History is full of examples where a biotech firm’s value has gone from 100 units to 0 units and the company eventually goes bankrupt. Only a rare few succeed. These are completely impossible to analyze as an outsider; you can crunch scenarios in Excel if you’re interested enough, and one of a hundred options will then materialize in some form. Understand this as a casino game (double or nothing), whereas index investing is the alternative where you don’t lose your capital over the long term.

Bioretec

Bioretec Ltd | Company announcement | 13 March 2026 at 5:15 p.m.Bioretec Ltd has today published its 2025 Financial Statements and Annual Report. The publications are attached to this release...

Bioretec Ltd&nbsp; | Company announcement | 13 March 2026 at 5:15 p.m.Bioretec Ltd has today published its 2025 Financial Statements and Annual Report. The publications are attached to this release and also available in Finnish and English on the company's website at investors.bioretec.com/en/reports_and_presentationsFor additional information:Sarah van Hellenberg Hubar-Fisher, CEO+31 6 1544 8736sarah.hubar-fisher@bioretec.comTuukka Paavola, CFO+358 50 386 0013tuukka.paavola@bioretec.comCertified AdviserNordic Certified Adviser AB, +46 70 551 67 29Information about BioretecBioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.&nbsp;The company's latest innovation, the RemeOs™ product line, is based on a high-performance magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The first RemeOs product market authorization was received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025.Bioretec's Activa product line features fully bioabsorbable orthopedic implants made from a proprietary, self-reinforced PLGA both CE marked and FDA cleared for a wide range of indications in adult and pediatric patients.Bioretec is shaping the future of orthopedic treatment with a focus on healing through absorption, paving the way for more effective and patient-friendly solutions.To learn more about Bioretec, visit&nbsp;<a href="https://www.bioretec.com/">www.bioretec.com</a>&nbsp;&nbsp; <div></div>